Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Restructuring, Ray Elliott Makes Boston Scientific His Own

This article was originally published in The Gray Sheet

Executive Summary

Facing what promises to be a very challenging 2010, Boston Scientific is revamping its management and cost structures, making major layoffs and setting the stage for a series of targeted divestures and acquisitions
Advertisement

Related Content

St. Jude Restructuring Will Cut 300 Jobs, Save Up To $60 Million In 2013
Boston Scientific Lays Out Near-Term Growth Plan
Boston Scientific Lays Out Near-Term Growth Plan
Boston Sci Controls New Asthma Device Market With Acquisition
Boston Scientific Tries To Climb Back Up From ICD Market Share Spill
People In Brief
Boston Scientific shops neuro businesses
Boston Scientific Confirms Manufacturing Changes That Led To ICD Recall
Boston Scientific Passes Baton: Former Zimmer Chief To Replace Tobin
Boston Scientific Passes Baton: Former Zimmer Chief To Replace Tobin

Topics

Advertisement
UsernamePublicRestriction

Register

MT028511

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel